1. Stent makers want government to apply differential pricing for drug-eluting stents

Stent makers want government to apply differential pricing for drug-eluting stents

Stent manufacturers want the government to apply differential pricing for drug-eluting stents by classifying them on the basis of technology used.

By: | New Delhi | Published: May 1, 2017 5:38 PM
These are considered superior over bare metal stents, which are a mesh-like tube of thin wires. (Reuters)

Stent manufacturers want the government to apply differential pricing for drug-eluting stents by classifying them on the basis of technology used. Such a move will reward quality and innovation to keep the segment viable while also giving physicians broader treatment options, according to two industry bodies — AdvaMed and MTaI.

Drug-eluting stents (DES) have a polymer coating over mesh that emits a drug over time that prevent blockage of arteries from recurring. These are considered superior over bare metal stents, which are a mesh-like tube of thin wires.

In February this year, the NPPA had brought stents under price control and capped their price at Rs 7,260 for bare metal variety and Rs 29,600 for DES. The corresponding average MRPs before the price control stood at Rs 45,100 and Rs 1.21 lakh respectively.

With the government rejecting applications from Abbott and Medtronic to withdraw their advanced DES, Medical Technology Association of India (MTaI) said if all the DES were treated as same on pricing front, then companies must be allowed to decide to what to sell in the market.

Advanced Medical Technology Association (AdvaMed) said the government must consider the innovative nature and provide differentiation among different generations of DES and not generalise “such a high tech and hugely important sector of medical devices”.

Watch this also:

 

“It is important to have a differential pricing model for making available multiple variants of DES offering varied benefits to patients and physicians,” AdvaMed said in a statement.

Suggesting three categories of DES, AdvaMed said Class I must be for majority of cases; Class II for complex cases and Class III for innovative ones. “This will ensure that patients have access to quality medical devices, physicians have broad treatment options to address complex diseases,” it said.

Moreover, with such classification, India’s nascent medical technology industry will be rewarded for introducing new and innovative technologies by securing the economic viability of desirable products, it added

Expressing similar views, MTaI said the National Pharmaceutical Pricing Authority (NPPA) had decided on one price for all drug-eluting stents on the basis that later generations of DES are not superior to earlier generations.

“So, if all the drug-eluting stents are the same, the industry should have some freedom in deciding which stents to market, as long as a broad range still stays available,” MTaI said in the statement.

  1. E
    Eve Fernandez
    May 2, 2017 at 5:04 pm
    These are not very great technologies that people cannot understand. Any well educated engineer can understand these things. We cannot leave the pricing to suppliers. Suppliers are fleecing because the application is critical. If you really see the fabrication and working principle will be much lesser in technology than a two wheeler, and LCD/LED TV, or a mobile smart phone. With high market demand ( high number of people undergoing angioplasty), the prices should be further reduced. Innovation is there in all field. It is not just in medical field alone
    Reply
  2. J
    Jayesh
    May 1, 2017 at 6:45 pm
    Only experts i.e. doctors can tell us what should be the policy. However, they are the one no one trust. Docs needs to work hard to earn their respect back. Events like strike by MARD doctors, Female Feticide at IMA verified facility at Sangli based doctor. We see no condemnation by medical fraternity on such issues is really regrettable. Not sure bureaucrats and politicians can really decide this policy if not scientist only can answer.
    Reply

Go to Top